341 related articles for article (PubMed ID: 33964937)
1. EMP3 mediates glioblastoma-associated macrophage infiltration to drive T cell exclusion.
Chen Q; Jin J; Huang X; Wu F; Huang H; Zhan R
J Exp Clin Cancer Res; 2021 May; 40(1):160. PubMed ID: 33964937
[TBL] [Abstract][Full Text] [Related]
2. ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.
Lailler C; Louandre C; Morisse MC; Lhossein T; Godin C; Lottin M; Constans JM; Chauffert B; Galmiche A; Saidak Z
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31467175
[TBL] [Abstract][Full Text] [Related]
3. EMP3 as a prognostic biomarker correlates with EMT in GBM.
Li L; Xia S; Zhao Z; Deng L; Wang H; Yang D; Hu Y; Ji J; Huang D; Xin T
BMC Cancer; 2024 Jan; 24(1):89. PubMed ID: 38229014
[TBL] [Abstract][Full Text] [Related]
4. Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma.
Jun F; Hong J; Liu Q; Guo Y; Liao Y; Huang J; Wen S; Shen L
Oncotarget; 2017 Feb; 8(9):14343-14358. PubMed ID: 27527869
[TBL] [Abstract][Full Text] [Related]
5. PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
Zhu Z; Zhang H; Chen B; Liu X; Zhang S; Zong Z; Gao M
Front Immunol; 2020; 11():588552. PubMed ID: 33329573
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target.
Wei J; Marisetty A; Schrand B; Gabrusiewicz K; Hashimoto Y; Ott M; Grami Z; Kong LY; Ling X; Caruso H; Zhou S; Wang YA; Fuller GN; Huse J; Gilboa E; Kang N; Huang X; Verhaak R; Li S; Heimberger AB
J Clin Invest; 2019 Jan; 129(1):137-149. PubMed ID: 30307407
[TBL] [Abstract][Full Text] [Related]
7. The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma.
Martija AA; Pusch S
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067658
[TBL] [Abstract][Full Text] [Related]
8. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.
Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S
Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817
[TBL] [Abstract][Full Text] [Related]
9. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P
J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669
[TBL] [Abstract][Full Text] [Related]
10. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
[TBL] [Abstract][Full Text] [Related]
11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
12. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
13. Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70.
Chahlavi A; Rayman P; Richmond AL; Biswas K; Zhang R; Vogelbaum M; Tannenbaum C; Barnett G; Finke JH
Cancer Res; 2005 Jun; 65(12):5428-38. PubMed ID: 15958592
[TBL] [Abstract][Full Text] [Related]
14. Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis.
Cui X; Morales RT; Qian W; Wang H; Gagner JP; Dolgalev I; Placantonakis D; Zagzag D; Cimmino L; Snuderl M; Lam RHW; Chen W
Biomaterials; 2018 Apr; 161():164-178. PubMed ID: 29421553
[TBL] [Abstract][Full Text] [Related]
15. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment.
Dumas AA; Pomella N; Rosser G; Guglielmi L; Vinel C; Millner TO; Rees J; Aley N; Sheer D; Wei J; Marisetty A; Heimberger AB; Bowman RL; Brandner S; Joyce JA; Marino S
EMBO J; 2020 Aug; 39(15):e103790. PubMed ID: 32567735
[TBL] [Abstract][Full Text] [Related]
16. EMP3 sustains oncogenic EGFR/CDK2 signaling by restricting receptor degradation in glioblastoma.
Martija AA; Krauß A; Bächle N; Doth L; Christians A; Krunic D; Schneider M; Helm D; Will R; Hartmann C; Herold-Mende C; von Deimling A; Pusch S
Acta Neuropathol Commun; 2023 Nov; 11(1):177. PubMed ID: 37936247
[TBL] [Abstract][Full Text] [Related]
17. High EMP3 expression might independently predict poor overall survival in glioblastoma and its expression is related to DNA methylation.
Yue H; Xu Q; Xie S
Medicine (Baltimore); 2018 Jan; 97(1):e9538. PubMed ID: 29505529
[TBL] [Abstract][Full Text] [Related]
18. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
Xuan Z; Fang L; Zhang G; Zhang X; Jiang J; Wang K; Huang P
J Mol Neurosci; 2023 Jan; 73(1):1-14. PubMed ID: 36542317
[TBL] [Abstract][Full Text] [Related]
19. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.
Liu Y; Li X; Zhang Y; Wang H; Rong X; Peng J; He L; Peng Y
Oncogene; 2019 Dec; 38(49):7399-7415. PubMed ID: 31427735
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
